领航医药生物科技中期报告 2023-2024

(IncorporatedintheCaymanIslandsandcontinuedinBermudawithlimitedliability)(于开曼群岛注册成立并于百慕大存续之有限公司) (StockCode股份代号：399) 2023/24 INTERIMREPORT 中期报告 Contents 目录 2CorporateInformation 公司资料 4Chairman’sStatement 主席报告 6ManagementDiscussionandAnalysis 管理层讨论及分析 17OtherInformationProvidedinAccordancewiththeListingRules 根据上市规则披露之其他资料 23CondensedConsolidatedStatementofProfitorLossandOtherComprehensiveIncome 简明综合损益及其他全面收益表 26CondensedConsolidatedStatementofFinancialPosition 简明综合财务状况表 29CondensedConsolidatedStatementofChangesinEquity 简明综合权益变动表 31CondensedConsolidatedStatementofCashFlows 简明综合现金流量表 32NotestotheCondensedConsolidatedFinancialStatements 简明综合财务报表附注 CorporateInformation 公司资料 BOARDOFDIRECTORS ExecutiveDirectors GaoYuanXingTangRongChengTakYiu Non-executiveDirectors JiangNian(Chairman) XiaoYanWuYanmin Independentnon-executiveDirectors ChenWeijunWangRongliangChenJinzhong AuditCommitteeChenWeijun(Chairman)WangRongliang ChenJinzhong RemunerationCommitteeWangRongliang(Chairman)JiangNian ChenJinzhong NominationCommittee JiangNian(Chairman)WangRongliangChenJinzhong HONORARYCHAIRMAN MaoYumin COMPANYSECRETARY PoonHonYin REGISTEREDOFFICE ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda 董事会 执行董事 高源兴唐榕郑德耀 非执行董事蒋年（主席）肖焱 邬燕敏 独立非执行董事 陈伟君王荣梁陈金中 审核委员会陈伟君（主席）王荣梁 陈金中 薪酬委员会王荣梁（主席）蒋年 陈金中 提名委员会蒋年（主席）王荣梁 陈金中 名誉主席 毛裕民 公司秘书 潘汉彦 注册办事处ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda 2INNOVATIVEPHARMACEUTICALBIOTECHLIMITED2023/24InterimReport CorporateInformation 公司资料 PRINCIPALPLACEOFBUSINESSINHONGKONG Unit2002,20thfloor OnHongCommercialBuilding145HennessyRoad WanChai,HongKong PRINCIPALSHAREREGISTRARANDTRANSFERAGENT ConyersCorporateServices(Bermuda)Limited ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda BRANCHSHAREREGISTRARANDTRANSFERAGENTINHONGKONG TricorTengisLimited 17/F,FarEastFinanceCentre16HarcourtRoad HongKong AUDITORS ElitePartnersCPALimited10/F,8ObservatoryRoadTsimShaTsui,KowloonHongKong PRINCIPALBANKER BankofCommunicationsCo.,Ltd. STOCKCODE 399 COMPANYWEBSITE www.ipb.asiawww.irasia.com/listco/hk/ipb 香港主要营业地点 香港湾仔 轩尼斯道145号安康商业大厦20楼2002室 股份登记总处及过户代理处 ConyersCorporateServices(Bermuda)Limited ClarendonHouse2ChurchStreet HamiltonHM11,Bermuda 香港股份登记分处及过户代理处 卓佳登捷时有限公司香港 夏悫道16号 远东金融中心17楼 核数师 开元信德会计师事务所有限公司香港 九龙尖沙咀 天文台道8号10楼 主要往来银行 交通银行股份有限公司 股份代号 399 公司网站 www.ipb.asiawww.irasia.com/listco/hk/ipb 2023/24年中期报告领航医药及生物科技有限公司3 Chairman’sStatement 主席报告 DearShareholders, Onbehalfoftheboard(the“Board”)ofdirectors(the“Directors”)ofInnovativePharmaceuticalBiotechLimited,(the“Company”,togetherwithitssubsidiaries,the“Group”),IherebypresenttoallshareholdersoftheCompany(the“Shareholders”)theunauditedconsolidatedfinancialresultsoftheGroupforthesixmonthsended30September2023(the“FinancialPeriod”)andthesixmonthsended30September2022(the“PreviousFinancialPeriod”). TheGrouponlyrecordedrevenueofapproximatelyHK$3.7millionfortheFinancialPeriod,adecreaseofapproximately9.7%inrevenuefromapproximatelyHK$4.1millionasrecordedinthePreviousFinancialPeriod. TheCompanyreportedaprofitforthePeriodamountedtoapproximatelyHK$193.7million,ascomparedwiththelossforthePreviousFinancialPeriodamountedtoapproximatelyHK$115.7million.ItisduetotheCompanycompletedthethirdamendmentoftheconvertiblebondwithprincipalamountofHK$715millionissuedbytheCompanyduringtheFinancialPeriod,anamountofapproximatelyHK$330.3millionnon-cashitemwascreditedintotheincomestatement. 各位股东： 本人谨代表领航医药及生物科技有限公司（“本公司”，连同其附属公司统称“本集团”）之董事（“董事”）会（“董事会”）向本公司所有股东（“股东”）提呈本集团截至二零二三年九月三十日止六个月（“本财政期间”）及截至二零二二年九月三十日止六个月（“上一财政期间”）之未经审核综合财务业绩。 本集团于本财政期间之收益仅为约3,700,000港元，较上一财政期间录得之收益约4,100,000港元减少约9.7%。 本公司于期内录得溢利约193,700,000港元，而上一财政期间则录得亏损约115,700,000港元。由于本公司于本财政期间完成本公司所发行本金额为715,000,000港元的可换股债券第三次修订，约330,300,000港元的非现金项目已计入收益表内。 4INNOVATIVEPHARMACEUTICALBIOTECHLIMITED2023/24InterimReport Chairman’sStatement 主席报告 OUTLOOK TheGroupalsoengagesindevelopmentofatechnologythatwouldallowinsulintobeadministeredorally.Thetechnologyisstillintheresearchanddevelopmentstage.TheGrouphascommencedthepartB,PhaseIIIoftheclinicaltrialinAugust2020whichistypicallyconsideredasthefinalstageofclinicaltrialbeforecommercialization.Currently,about300patientshaveparticipatedintheclinicaltrial.TheGroupwilluseitsbestendeavourstocommercialisetheproductbythefirstquarterof2025. TheCompanycontinuestoactivelypursueandreviewcooperation,jointventures,andinvestmentswithsuitablepartnersandwillcontinuetofocusonimprovingtheGroup’sattractivenessandprofitabilityasnecessarytoenhanceshareholderreturnsandthesustainablelong-termdevelopmentoftheGroupasawhole. APPRECIATION OnbehalfofallthemembersoftheBoard,IwouldliketotakethisopportunitytoexpressmygratitudetotheShareholdersandbusinesspartnersoftheGroupfortheircontinuedsupportandtrustduringthepastyears,andmymostsincereappreciationtothedirectors,management,andstaffatalllevelsfortheirdedication,hardwork,andcontributionstotheGroup. JiangNian Chairman Shanghai,29November2023 展望 本集团亦致力于开发一种令胰岛素可透过口服方式服用之技术。该技术仍处于研发阶段。本集团已于二零二零年八月开始临床试验第三期B段，其通常被视为商业化临床试验之最后阶段。目前，约有300名患者参与临床试验。本集团将尽最大努力于二零二五年第一季度将该产品商业化。 本公司继续积极物色及检讨合作、合资企业及投资